Author

Casey C. Lynch

Observed names: CASEY LYNCH, Casey C Lynch, Casey Lynch

Observed institutions: University of California, San Francisco, CytomX Therapeutics (United States), Surrozen, Inc. (United States), Stanford University

OpenAlex ID: A5007873239

Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors

2019 · Stephen S. Dominy, Casey Lynch, et al. · Science Advances · 1,987

Nerve Growth Factor Signaling in Caveolae-like Domains at the Plasma Membrane

1999 · Chin-shiou Huang, Jie Zhou, et al. · Journal of Biological Chemistry · 134

Alzheimer’s Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains

2020 · Ursula Haditsch, Theresa Roth, et al. · Journal of Alzheimer s Disease · 110

Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine‐gingipain inhibitor COR388

2020 · Shirin Arastu‐Kapur, Mai Nguyen, et al. · Pharmacology Research & Perspectives · 30

Comprehensive Theory of Alzheimer's Disease: The Effects of Cholesterol on Membrane Receptor Trafficking

2000 · CASEY LYNCH, WILLIAM MOBLEY · Annals of the New York Academy of Sciences · 23

COR388, a novel gingipain inhibitor, decreases fragmentation of APOE in the central nervous system of Alzheimer’s disease patients

2020 · Debasish Raha, Sean Broce, et al. · Alzheimer s & Dementia · 11

COR388 for the Treatment of Alzheimer’s Disease (4098)

2020 · Michael Detke, Casey Lynch, et al. · Neurology · 5

P4‐542: Utility of Speech‐based Digital Biomarkers for Evaluating Disease Progression in Clinical Trials of Alzheimer's Disease

2019 · William Simpson, Liam Kaufman, et al. · Alzheimer s & Dementia · 4

Gingipains Identified in Alzheimer's Disease Brains Differentially Fragment ApoE Proteins

2021 · Debasish Raha, Sean Broce, et al. · SSRN Electronic Journal · 3

Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, A Second‐Generation Gingipain Inhibitor for the Treatment of P. Gingivalis ‐ Positive Alzheimer Dementia

2023 · Michael Detke, Marwan Sabbagh, et al. · Alzheimer s & Dementia · 1

676 PD-L1 is induced by the periodontal pathogen porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat

2020 · Shirin Arastu-Kapur, Mai Nguyen, et al. · Journal for ImmunoTherapy of Cancer · 1

Targeting porphyromonas gingivalis to treat Alzheimer’s disease and comorbid cardiovascular disease

2020 · Florian Ermini, Paola Rojas, et al. · Alzheimer s & Dementia

Comprehensive Alzheimer’s pathology is induced by P. gingivalis infection: COR388 and other gingipain inhibitors protect against synaptic loss

2020 · Florian Ermini, Ursula Haditsch, et al. · Alzheimer s & Dementia

P4‐663: Initiation of the Phase 2/3 Gain Trial of Cor388, a Novel Bacterial Virulence Factor Inhibitor for the Treatment of Alzheimer's Disease (ad) Based on Phase I A/b Safety, Pk, Biomarker and Efficacy Data

2019 · Mike Detke, Casey Lynch, et al. · Alzheimer s & Dementia

Works count: 14

Citation count: 2,309

H-index: 6

I10-index: 6